Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 3NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Interventional × PX-866 × Clear all
NCT01259869 2023-08-22

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Canadian Cancer Trials Group

Phase 2 Completed
34 enrolled 7 charts
CNS

Glioblastoma

NCT01331083 2023-08-22

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Completed
68 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT00726583 2018-05-17

Phase I Trial of Oral PX-866

Seagen Inc.

Phase 1 Completed
90 enrolled

Carcinoma, Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01204099 2018-05-16

Study of PX-866 and Docetaxel in Solid Tumors

Seagen Inc.

Phase 1/2 Completed
223 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡